OTCMKTS:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis $0.03 +0.02 (+24,900.00%) As of 02:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Vaxxinity Stock (OTCMKTS:VAXX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaxxinity alerts:Sign Up Key Stats Today's Range$0.00▼$0.0350-Day Range$0.00▼$0.0652-Week Range$0.00▼$0.20Volume3,937 shsAverage Volume3,350 shsMarket Capitalization$3.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaxxinity, Inc. is a biotechnology company focused on developing active immunotherapies, including therapeutic vaccines, for chronic diseases. The company’s research is centered on treatments designed to stimulate the immune system to target disease-associated proteins while potentially offering longer-lasting effects than conventional therapies. Vaxxinity’s pipeline has focused primarily on neurodegenerative disorders. Its programs have included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine targeting alpha-synuclein for Parkinson’s disease and related disorders. The company has also explored immunotherapy approaches for chronic pain and other conditions. The company was formed from the United Neuroscience biotechnology platform and has conducted research and clinical development activities in the United States and internationally. Vaxxinity was co-founded by Mei Mei Hu, who has served as chief executive officer, and Lou Reese, who has held senior leadership roles within the company. Its products remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAXX Stock News HeadlinesVaxxinity Inc.May 25, 2026 | marketwatch.comBrain healthOctober 24, 2024 | newsweek.comNA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 16 at 1:00 AM | Porter & Company (Ad)Treatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comSee More Headlines VAXX Stock Analysis - Frequently Asked Questions How have VAXX shares performed this year? Vaxxinity's stock was trading at $0.0003 at the start of the year. Since then, VAXX shares have increased by 8,233.3% and is now trading at $0.0250. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (OTCMKTS:VAXX) announced its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxxinity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxxinity investors own include NVIDIA (NVDA), Roblox (RBLX), Palantir Technologies (PLTR), Rivian Automotive (RIVN), Tesla (TSLA), Robinhood Markets (HOOD) and IREN (IREN). Company Calendar Last Earnings3/27/2023Today10/16/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:VAXX Previous SymbolNASDAQ:VAXX CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees90Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares126,750,000Free Float45,553,000Market Cap$3.17 million OptionableNot Optionable Beta-74.42 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:VAXX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts